{
    "root": "6471df09-2ee1-43c4-8335-0a7a9fc5bbd4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Losartan Potassium",
    "value": "20250520",
    "ingredients": [
        {
            "name": "LOSARTAN POTASSIUM",
            "code": "3ST302B24A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "2165RE0K14"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of      hypertension, to lower blood pressure in adults and children greater than      6 years old. Lowering blood pressure reduces the risk of fatal and      nonfatal cardiovascular events, primarily strokes and myocardial      infarctions. ( 1.1 ) • Reduction of      the risk of stroke in patients with hypertension and left ventricular      hypertrophy. There is evidence that this benefit does not apply to Black      patients. ( 1.2 ) • Treatment of      diabetic nephropathy with an elevated serum creatinine and proteinuria in      patients with type 2 diabetes and a history of hypertension. ( 1.3 )",
    "contraindications": "Hypertension • Usual adult dose: 50 mg once      daily. ( 2.1 ) • Usual pediatric starting dose:      0.7 mg per kg once daily (up to 50 mg). ( 2.1 ) Hypertensive Patients with Left Ventricular Hypertrophy • Usual starting dose: 50 mg once      daily. ( 2.2 ) • Add hydrochlorothiazide 12.5 mg      and/or increase losartan potassium to 100 mg followed by an increase to      hydrochlorothiazide 25 mg if further blood pressure response is needed. ( 2.2 , 14.2 ) Nephropathy in Type 2 Diabetic Patients • Usual dose: 50 mg once daily. ( 2.3 ) • Increase dose to 100 mg once      daily if further blood pressure response is needed. ( 2.3 )",
    "warningsAndPrecautions": "Losartan Potassium Tablets USP, 25 mg are white to off-white, capsule-shaped, film-coated tablets debossed with the logo of \"Z\" on one side and \"2\"on other side and are supplied as follows:\n                  Overbagged with 10 film-coated tablets per bag, NDC 55154-2326-0\n                  Losartan Potassium Tablets USP, 50 mg are white to off-white, capsule-shaped, film-coated tablets debossed with the logo of \"Z16\" on one side and lip type breakline on other side and are supplied as follows:\n                  Overbagged with 10 film-coated tablets per bag, NDC 55154-2327-0\n                  Losartan Potassium Tablets USP, 100 mg are white to off-white, capsule-shaped, film-coated tablets debossed with the logo of \"Z18\" on one side and plain on other side and are supplied as follows:\n                  Overbagged with 10 film-coated tablets per bag, NDC 55154-2333-0\n                  WARNING: These Unit Dose packages are not child resistant and are Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                     Storage:\n                  \n                  Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.\n                  Dispense in a tight, light-resistant container.",
    "adverseReactions": "• Hypersensitivity to any      component. ( 4 ) • Coadministration with aliskiren      in patients with diabetes. ( 4 )"
}